ESR1 and prostate neoplasm: Here, using androgen receptor (AR)-positive LNCaP and oestrogen receptor alpha (ERα)-expressing PC-3 prostate tumour cells, we have analysed whether the antiproliferative activity of RES takes place by inhibition of the AR- or ERα-dependent PI3K pathway.